Immutep Announces Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2025
Immutep (NASDAQ: IMMP) announced the acceptance of three abstracts for presentation at the European Society for Medical Oncology (ESMO) Congress 2025 in Berlin. The presentations will showcase clinical trials of their first-in-class MHC Class II agonist, eftilagimod alfa (efti).
The presentations include a Proffered Paper oral presentation on the EFTISARC-NEO Phase II trial in soft tissue sarcoma, a poster presentation on the INSIGHT-003 Phase I trial in first-line non-small cell lung cancer (NSCLC), and a Trials in Progress ePoster on the pivotal TACTI-004 Phase III trial in first-line NSCLC. The abstracts will be available on October 13, 2025.
Immutep (NASDAQ: IMMP) ha annunciato l'accettazione di tre abstract per la presentazione al Congresso della European Society for Medical Oncology (ESMO) 2025 a Berlino. Le presentazioni mostreranno studi clinici sul loro agonista di classe MHC di tipo II, eftilagimod alfa (efti), primo nel suo genere.
Le presentazioni includono una presentazione orale Proffered Paper sullo studio di Fase II EFTISARC-NEO nel sarcoma dei tessuti molli, una presentazione poster sullo studio di Fase I INSIGHT-003 nel carcinoma polmonare non a piccole cellule (NSCLC) in prima linea, e un ePoster Trials in Progress sullo studio pivotale di Fase III TACTI-004 nel NSCLC in prima linea. Gli abstract saranno disponibili il 13 ottobre 2025.
Immutep (NASDAQ: IMMP) anunci贸 la aceptaci贸n de tres res煤menes para su presentaci贸n en el Congreso de la Sociedad Europea de Oncolog铆a M茅dica (ESMO) 2025 en Berl铆n. Las presentaciones mostrar谩n ensayos cl铆nicos de su agonista de clase MHC II, eftilagimod alfa (efti), pionero en su tipo.
Las presentaciones incluyen una presentaci贸n oral Proffered Paper sobre el ensayo de Fase II EFTISARC-NEO en sarcoma de tejidos blandos, una presentaci贸n en p贸ster sobre el ensayo de Fase I INSIGHT-003 en c谩ncer de pulm贸n no microc铆tico (NSCLC) de primera l铆nea, y un ePoster Trials in Progress sobre el ensayo pivotal de Fase III TACTI-004 en NSCLC de primera l铆nea. Los res煤menes estar谩n disponibles el 13 de octubre de 2025.
Immutep (NASDAQ: IMMP)電� 2025雲� 氩犽ゼ毽办棎靹� 鞐措Μ電� 鞙犽熃膦呾枒頃欗殞(ESMO) 2025 頃欖垹雽�須�鞐愳劀 氚滍憸頃� 靹� 臧滌潣 齑堧鞚� 毂勴儩霅橃棃鞚岇潉 氚滍憸頄堨姷雼堧嫟. 鞚措矆 氚滍憸鞐愳劀電� 斓滌磮鞚� MHC 韥措灅鞀� II 鞛戩毄鞝滌澑 eftilagimod alfa (efti)鞚� 鞛勳儊 鞁滍棙 瓴瓣臣毳� 靹犽炒鞚� 鞓堨爼鞛呺媹雼�.
氚滍憸電� 鞐办“歆� 鞙§鞐� 雽�頃� EFTISARC-NEO 2靸� 鞁滍棙鞐� 甏�頃� Proffered Paper 甑憪 氚滍憸, 1彀� 牍勳唽靹疙彫韽愳晹(NSCLC)鞐愳劀鞚� INSIGHT-003 1靸� 鞁滍棙鞐� 甏�頃� 韽姢韯� 氚滍憸, 攴鸽Μ瓿� 1彀� NSCLC鞐愳劀鞚� 欷戩稊鞝� TACTI-004 3靸� 鞁滍棙鞐� 甏�頃� Trials in Progress ePoster搿� 甑劚霅橃柎 鞛堨姷雼堧嫟. 齑堧鞚� 2025雲� 10鞗� 13鞚检棎 瓿店皽霅� 鞓堨爼鞛呺媹雼�.
Immutep (NASDAQ : IMMP) a annonc茅 l'acceptation de trois r茅sum茅s pour pr茅sentation au Congr猫s de la Soci茅t茅 Europ茅enne d鈥橭ncologie M茅dicale (ESMO) 2025 脿 Berlin. Les pr茅sentations mettront en avant des essais cliniques de leur agoniste de classe MHC II innovant, eftilagimod alfa (efti).
Les pr茅sentations comprennent une communication orale Proffered Paper sur l'essai de phase II EFTISARC-NEO dans le sarcome des tissus mous, une pr茅sentation par poster sur l'essai de phase I INSIGHT-003 dans le cancer du poumon non 脿 petites cellules (NSCLC) en premi猫re ligne, ainsi qu鈥檜n ePoster Trials in Progress sur l鈥檈ssai pivot de phase III TACTI-004 en premi猫re ligne du NSCLC. Les r茅sum茅s seront disponibles 脿 partir du 13 octobre 2025.
Immutep (NASDAQ: IMMP) gab die Annahme von drei Abstracts f眉r Pr盲sentationen auf dem European Society for Medical Oncology (ESMO) Kongress 2025 in Berlin bekannt. Die Pr盲sentationen werden klinische Studien zu ihrem neuartigen MHC Klasse II Agonisten, eftilagimod alfa (efti), vorstellen.
Die Pr盲sentationen umfassen eine Proffered Paper m眉ndliche Pr盲sentation zur EFTISARC-NEO Phase-II-Studie bei Weichteilsarkomen, eine 笔辞蝉迟别谤辫谤盲蝉别苍迟补迟颈辞苍 zur INSIGHT-003 Phase-I-Studie in der Erstlinienbehandlung des nicht-kleinzelligen Lungenkarzinoms (NSCLC) sowie ein Trials in Progress ePoster zur entscheidenden TACTI-004 Phase-III-Studie in der Erstlinienbehandlung von NSCLC. Die Abstracts werden ab dem 13. Oktober 2025 verf眉gbar sein.
- None.
- None.
Insights
Immutep's ESMO presentations signal potential clinical progress for efti across multiple cancer indications, with the high-profile oral presentation suggesting promising data.
Immutep's upcoming presence at ESMO 2025 with three abstract presentations represents a significant development in their clinical program for eftilagimod alfa (efti). The acceptance of a Proffered Paper oral presentation for the EFTISARC-NEO Phase II trial is particularly noteworthy, as ESMO reserves these slots for data of "superior quality." This suggests the trial investigating efti with pembrolizumab and radiotherapy in resectable soft tissue sarcoma has generated compelling results.
The company will also present a poster with updated data from INSIGHT-003, their Phase I trial evaluating efti combined with first-line chemo-immunotherapy in metastatic non-squamous NSCLC. The third abstract, a Trials in Progress ePoster for their pivotal TACTI-004 Phase III study, highlights the company's advancement into late-stage development in first-line NSCLC, a substantial commercial opportunity.
Efti's mechanism as a first-in-class MHC Class II agonist represents a novel approach in immuno-oncology. Its evaluation in combination with pembrolizumab across multiple solid tumor types indicates Immutep's strategy to position efti as a potential complement to existing checkpoint inhibitor therapies.
For investors, these presentations constitute important near-term catalysts that could impact the company's valuation based on the quality of data presented. The pivotal Phase III trial in NSCLC will be particularly important to watch as positive outcomes could lead to regulatory approval in a major oncology indication.
SYDNEY, AUSTRALIA, July 28, 2025 (GLOBE NEWSWIRE) -- (ASX: IMM; NASDAQ: IMMP) (鈥淚mmutep鈥� or 鈥渢he Company鈥�), a late-stage immunotherapy company targeting cancer and autoimmune diseases, today announces three abstracts for clinical trials evaluating its first-in-class MHC Class II agonist, eftilagimod alfa (efti), have been accepted for presentation at the European Society for Medical Oncology (ESMO) Congress 2025 taking place 17-21 October in Berlin, Germany.
A Proffered Paper oral presentation will detail results from EFTISARC-NEO, a Phase II investigator-initiated trial in resectable soft tissue sarcoma, and data from the INSIGHT-003 Phase I investigator-initiated trial in first-line non-small cell lung cancer (1L NSCLC) has been accepted for poster presentation. Additionally, an abstract on the Company鈥檚 pivotal TACTI-004 Phase III in 1L NSCLC has been accepted for a Trials in Progress ePoster. Details of the presentations are as follows:
| Title: | EFTISARC-NEO: A phase II study of neoadjuvant eftilagimod alpha, pembrolizumab and radiotherapy in patients with resectable soft tissue sarcoma |
| Presenter: | Katarzyna Kozak, M.D., Ph.D., Maria Sklodowska-Curie National Research Institute of Oncology, Warsaw, Poland |
| Session Category: | Proffered Paper |
| Session Title: | Sarcoma |
| Presentation #: | 2686O |
| Date and Time: | Sunday, 19 October 2025 at 16:30 鈥� 18:00 PM CET |
| 听 | 听 |
| Title: | Eftilagimod alpha (soluble LAG-3 protein) combined with 1st line chemo- immunotherapy in metastatic non-squamous non-small cell lung cancer (NSCLC) 鈥� Updates from INSIGHT-003 (IKF614) |
| Presenter: | Dr. med. Akin Atmaca, Department of Hematology and Oncology, Krankenhaus Nordwest, UCT-University Cancer Center, Frankfurt, Germany |
| Session Category: | Poster |
| Session Title: | NSCLC, metastatic |
| Presentation #: | 1857P |
| Date and Time: | Saturday, 18 October 2025 at 12:00 鈥� 12:45 PM CET |
| 听 | 听 |
| Title: | TACTI-004, a double-blinded, randomised phase 3 trial of eftilagimod alfa plus pembrolizumab (P) + chemotherapy (C) vs placebo + P + C in 1st line advanced/metastatic NSCLC |
| Presenter: | Prof. Dr. med. Hans-Georg Kopp, Robert Bosch Hospital, Stuttgart, Germany |
| Session Category: | ePoster |
| Session Title: | NSCLC, metastatic |
| Presentation #: | 2086eTiP |
| 听 | 听 |
Proffered听Papers at ESMO are oral presentations of original data of superior quality, followed by expert discussion and perspectives.
Abstracts will be made available on the ESMO website on 13 October 2025 at 00.05 CET. The posters will be available on the Posters & Publications section of Immutep鈥檚 website after their presentations.
About Immutep
Immutep is a late-stage biotechnology company developing novel immunotherapies for cancer and autoimmune disease. The Company is a pioneer in the understanding and advancement of therapeutics related to Lymphocyte Activation Gene-3 (LAG-3), and its diversified product portfolio harnesses LAG-3鈥檚 ability to stimulate or suppress the immune response. Immutep is dedicated to leveraging its expertise to bring innovative treatment options to patients in need and to maximise value for shareholders. For more information, please visit .
Australian Investors/Media:
Eleanor Pearson, Sodali & Co.
+61 2 9066 4071;
U.S. Media:
Chris Basta, VP, Investor Relations and Corporate Communications
+1 (631) 318 4000;
FAQ
When and where will Immutep (IMMP) present at ESMO Congress 2025?
What clinical trials will Immutep (IMMP) present at ESMO 2025?
What is eftilagimod alfa (efti) being developed for by Immutep?
When will the ESMO 2025 abstracts for Immutep (IMMP) be available?
